SUNNYVALE, Calif., Sept. 29 — Cepheid (Nasdaq: CPHD) today announced it has received clearance from the U.S. Food & Drug Administration (FDA) to market its Xpert(TM) MRSA/SA Skin and Soft Tissue Infection (SSTI) test, which runs on the GeneXpert(R) System, for the rapid detection of Methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus (SA, typically Methicillin-sensitive) […]
Clarient, Inc. (Nasdaq:CLRT) and Definiens, Inc. jointly announced today that they established a strategic partnership to employ a series of image analysis platforms for Clarient’s in-house research and development, and Web-based customer portal PATHSiTE(SM). Under a five year collaborative agreement, Clarient and Definiens plan to develop and commercialize tools that will help to evaluate quantitative […]
e2v biosensors, a subsidiary of e2v technologies plc, and AbD Serotec, the division for research and diagnostic antibodies of MorphoSys AG, today launched a research programme to establish e2v’s proprietary biosensor system Visucare™, a novel detection technology for biomarkers using a single-antibody immunoassay. The Visucare™ system will be used for protein quantification in point of […]
PHILADELPHIA — Researchers have demonstrated a new instrument that makes it possible to detect and quantify multiple different clinically important proteins in a single tumor sample using conventional staining. Currently, pathologists usually need a separate tissue slice for each protein they want to examine, making it impossible to see how molecules interact within individual cells. […]
Sequenom, Inc. (NASDAQ:SQNM), a leading provider of genetic-analysis and molecular diagnostic solutions, announced additional, positive results from screening studies using the Company’s noninvasive circulating cell-free fetal (ccff) nucleic acid SEQureDx(TM) Technology, which enables the detection of fetal aneuploidy, including Down syndrome from maternal blood, at its Analyst Briefing in New York City. Among the data […]
WOBURN, Mass., Sept. 23 — U.S. Genomics today announced it has received a $4.5 million equity investment from BD (Becton, Dickinson and Company) and that the companies have entered into a strategic collaboration for development of a novel infectious disease diagnostic platform. The collaboration will focus on application of U.S. Genomics’ DirectLinear Analysis(TM) technology (DLA) […]
Acquisition of Center for Molecular Medicine Positions Sequenom for Commercial Launch of SEQureDx(TM) Test in First Half 2009 Daniel H. Farkas, Ph.D. to Join Sequenom Management Team SAN DIEGO–Sequenom (NASDAQ:SQNM – News) today announced that it entered into an agreement to acquire the Center for Molecular Medicine (CMM), a Clinical Laboratory Improvement Act (CLIA) certified […]
Sequenom, Inc. (Nasdaq: SQNM) today announced that it has secured exclusive rights to fundamental patent rights for digital PCR technologies and methods through a licensing agreement with Genomic Nanosystems, LLC, a wholly owned subsidiary of the Cytonix Corporation. The exclusively licensed rights include United States Patent Nos. 6,143,496 and 6,391,559 and pending applications. The license […]
Omaha, NE, and Charlottesville, VA, September 16, 2008 – Transgenomic (OTC-Bulletin Board: TBIO.OB) today announced a partnership with Key Genomics to develop a molecular diagnostic test which will guide clinicians in their choice of currently available treatments for ovarian cancer. The new test will be powered by Key Genomics’ predictive algorithm, COXEN (‘‘CO-eXpression ExtrapolatioN’’). Ovarian […]
Sequenom, Inc. (Nasdaq: SQNM), a leading provider of genetic-analysis solutions, today announced that it has acquired exclusive worldwide rights (excluding Hong Kong) to digital PCR and other noninvasive prenatal diagnostic intellectual property from The Chinese University of Hong Kong. These newly acquired rights expand Sequenom’s existing, broad intellectual property portfolio of noninvasive prenatal diagnostic methods […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
